Autolus Therapeutics (AUTL) Stock Price, News & Analysis $4.36 +0.28 (+6.86%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$3.90▼$4.4850-Day Range$2.13▼$4.8052-Week Range$1.60▼$4.83Volume1.03 million shsAverage Volume1.06 million shsMarket Capitalization$758.38 millionP/E RatioN/ADividend YieldN/APrice Target$8.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Autolus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside87.3% Upside$8.17 Price TargetShort InterestHealthy0.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.08Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.99) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector387th out of 933 stocksBiological Products, Except Diagnostic Industry64th out of 160 stocks 3.5 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.17, Autolus Therapeutics has a forecasted upside of 87.3% from its current price of $4.36.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.85% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 0.68%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 2.2 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Autolus Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for AUTL on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows1 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.78% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.99) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Autolus Therapeutics Stock (NASDAQ:AUTL)Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.Read More AUTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUTL Stock News HeadlinesDecember 10, 2023 | americanbankingnews.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.08December 9, 2023 | finance.yahoo.comAutolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023December 10, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 4, 2023 | americanbankingnews.comAutolus Therapeutics plc (NASDAQ:AUTL) Receives Consensus Recommendation of "Buy" from BrokeragesDecember 1, 2023 | americanbankingnews.comAutolus Therapeutics (NASDAQ:AUTL) Stock Rating Reaffirmed by Needham & Company LLCNovember 29, 2023 | markets.businessinsider.comBuy Rating for Autolus Therapeutics Backed by Promising Obe-cel Developments and Favorable Safety ProfileNovember 27, 2023 | marketwatch.comAutolus Seeks FDA OK of Obe-Cel in Adult B-Cell Acute Lymphoblastic LeukemiaNovember 27, 2023 | finance.yahoo.comAutolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)December 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 15, 2023 | markets.businessinsider.comPromising Outlook for Autolus Therapeutics: Buy Rating Based on Commercial Progress and Market Expansion OpportunitiesNovember 15, 2023 | finance.yahoo.comAutolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023November 10, 2023 | msn.comDeutsche Bank Initiates Coverage of Autolus Therapeutics plc - ADR (AUTL) with Buy RecommendationNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Autolus Therapeutics (AUTL) and Elanco Animal Health (ELAN)November 8, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday TradingNovember 6, 2023 | finance.yahoo.comInvestors in Autolus Therapeutics (NASDAQ:AUTL) from five years ago are still down 88%, even after 50% gain this past weekNovember 6, 2023 | finance.yahoo.comAutolus Therapeutics announces participation in upcoming conferencesNovember 5, 2023 | finance.yahoo.comAutolus Therapeutics plc (NASDAQ:AUTL) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chimerix (CMRX), Rani Therapeutics Holdings (RANI) and Autolus Therapeutics (AUTL)November 2, 2023 | seekingalpha.comAutolus Therapeutics plc 2023 Q3 - Results - Earnings Call PresentationNovember 2, 2023 | finance.yahoo.comAutolus Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 2, 2023 | finance.yahoo.comAutolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster PresentationsOctober 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Evolent Health (EVH), Autolus Therapeutics (AUTL) and HCA Healthcare (HCA)October 17, 2023 | finance.yahoo.comAutolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosusOctober 11, 2023 | finance.yahoo.comCorrection - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023October 11, 2023 | finance.yahoo.comAutolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023October 10, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Sharply TuesdaySeptember 11, 2023 | seekingalpha.comAutolus: CAR-T Therapy Looks PromisingSee More Headlines Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees399Year FoundedN/APrice Target and Rating Average Stock Price Target$8.17 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+87.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-148,840,000.00 Net MarginsN/A Pretax Margin-3,180.50% Return on Equity-64.86% Return on Assets-35.01% Debt Debt-to-Equity RatioN/A Current Ratio8.21 Quick Ratio8.21 Sales & Book Value Annual Sales$6.36 million Price / Sales119.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book2.52Miscellaneous Outstanding Shares173,940,000Free Float129,235,000Market Cap$758.38 million OptionableNot Optionable Beta1.69 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Christian Martin Itin Ph.D. (Age 59)CEO & Director Comp: $2.15MDr. Martin Pule M.D. (Age 51)MBBS, Founder, Senior VP & Chief Scientific Officer Mr. Christopher Vann (Age 58)Senior VP & COO Mr. David Brochu (Age 67)Senior VP & Chief Technical Officer Mr. Brent Rice (Age 57)Senior VP, Chief Commercial Officer & Site Head of US Dr. Edgar E. W. Braendle M.D. (Age 63)Ph.D., Senior VP & Chief Development Officer Mr. Robert F. Dolski (Age 53)Chief Financial Officer Ms. Olivia ManserDirector of Investor RelationsDr. Chris Williams (Age 43)Senior Vice President of Corporate Development Mr. Alexander SwanChief Human Resources OfficerMore ExecutivesKey CompetitorsImmaticsNASDAQ:IMTXHilleVaxNASDAQ:HLVXCabaletta BioNASDAQ:CABANovavaxNASDAQ:NVAXAnavex Life SciencesNASDAQ:AVXLView All CompetitorsInstitutional OwnershipB. Riley Wealth Advisors Inc.Sold 5,000 shares on 12/1/2023Ownership: 0.010%Armistice Capital LLCSold 364,000 shares on 11/15/2023Ownership: 3.973%Affinity Asset Advisors LLCBought 403,449 shares on 11/15/2023Ownership: 1.147%Laurion Capital Management LPSold 23,894 shares on 11/15/2023Ownership: 0.853%Tower Research Capital LLC TRC Sold 7,680 shares on 11/14/2023Ownership: 0.010%View All Institutional Transactions AUTL Stock Analysis - Frequently Asked Questions Should I buy or sell Autolus Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUTL shares. View AUTL analyst ratings or view top-rated stocks. What is Autolus Therapeutics' stock price target for 2024? 7 analysts have issued twelve-month target prices for Autolus Therapeutics' stock. Their AUTL share price targets range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $8.17 in the next twelve months. This suggests a possible upside of 87.3% from the stock's current price. View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts. How have AUTL shares performed in 2023? Autolus Therapeutics' stock was trading at $1.90 at the beginning of the year. Since then, AUTL stock has increased by 129.5% and is now trading at $4.36. View the best growth stocks for 2023 here. When is Autolus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our AUTL earnings forecast. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) released its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The firm had revenue of $0.41 million for the quarter, compared to analysts' expectations of $2 million. What ETF holds Autolus Therapeutics' stock ? Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD). When did Autolus Therapeutics IPO? (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (3.97%), Affinity Asset Advisors LLC (1.15%), Perpetual Ltd (1.14%), Laurion Capital Management LP (0.85%), Lynx1 Capital Management LP (0.78%) and Schonfeld Strategic Advisors LLC (0.17%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AUTL) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.